Brokerages Set Bristol Myers Squibb Company (NYSE:BMY) Price Target at $54.62

Shares of Bristol Myers Squibb Company (NYSE:BMY) have earned a consensus rating of “Hold” from the twenty-one brokerages that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, fourteen have assigned a hold recommendation and six have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $54.6154.

A number of research analysts recently weighed in on BMY shares. HSBC reiterated a “hold” rating and issued a $53.00 price objective on shares of Bristol Myers Squibb in a research note on Wednesday, December 10th. Guggenheim reiterated a “buy” rating on shares of Bristol Myers Squibb in a research note on Tuesday. Cantor Fitzgerald restated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Monday, November 24th. Scotiabank reaffirmed a “sector perform” rating and set a $53.00 target price (up previously from $45.00) on shares of Bristol Myers Squibb in a report on Thursday, December 4th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Bristol Myers Squibb in a report on Tuesday, October 14th.

Bristol Myers Squibb Trading Down 0.1%

Shares of BMY opened at $54.65 on Wednesday. Bristol Myers Squibb has a fifty-two week low of $42.52 and a fifty-two week high of $63.33. The business has a 50-day moving average of $48.83 and a 200 day moving average of $47.37. The firm has a market cap of $111.26 billion, a P/E ratio of 18.46, a price-to-earnings-growth ratio of 8.37 and a beta of 0.29. The company has a debt-to-equity ratio of 2.39, a quick ratio of 1.17 and a current ratio of 1.27.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, topping analysts’ consensus estimates of $1.52 by $0.11. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. The firm had revenue of $12.22 billion during the quarter, compared to analyst estimates of $11.75 billion. During the same quarter last year, the business earned $1.80 earnings per share. The company’s quarterly revenue was up 2.8% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. As a group, research analysts forecast that Bristol Myers Squibb will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd will be paid a $0.63 dividend. The ex-dividend date is Friday, January 2nd. This represents a $2.52 annualized dividend and a yield of 4.6%. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s dividend payout ratio is currently 83.78%.

Institutional Investors Weigh In On Bristol Myers Squibb

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Trifecta Capital Advisors LLC bought a new position in Bristol Myers Squibb in the 2nd quarter worth about $25,000. Darwin Wealth Management LLC bought a new position in shares of Bristol Myers Squibb in the second quarter worth approximately $25,000. CBIZ Investment Advisory Services LLC raised its stake in Bristol Myers Squibb by 66.0% in the first quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 231 shares in the last quarter. GKV Capital Management Co. Inc. bought a new stake in Bristol Myers Squibb during the first quarter valued at approximately $36,000. Finally, Harbor Capital Advisors Inc. grew its stake in Bristol Myers Squibb by 107.2% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 313 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.